Medindia

X

Edison Issues Update on International Stem Cell (ISCO)

Tuesday, August 2, 2016 Genetics & Stem Cells News J E 4
Advertisement

LONDON, August 2, 2016 /PRNewswire/ --

International Stem Cell announced in July 2016 that it had dosed the first patient in the Phase I dose escalation study examining its neural stem cell product ISC-hpNSC for the treatment of moderate to severe Parkinson's disease. The study will enrol 12 patients at three dosing regimens with a primary endpoint of safety, but will provide preliminary efficacy data measured at six and 12 months following the treatment.

     (Logo: http://photos.prnewswire.com/prnh/20130417/608168 )

We have increased our valuation to $28m (from $27m), but have reduced the valuation per basic share to $8.75 (from $9.60). This reflects higher cash ($1.5m vs $0.5m) offset by an increase in the number of shares (3.2m vs 2.8m previously). Otherwise our valuation remains unchanged. There remain approximately 19m in potentially dilutive shares from warrants, options and convertible preferred stock. We maintain that the company will need at least $76m in additional financing before profitability in 2024.

Click here to view the full report.

All reports published by Edison are available to download free of charge from its website http://www.edisoninvestmentresearch.com.

About Edison: Edison is an international equity research firm with a team of over 110 analysts, investment and roadshow professionals and works with both large and smaller capitalised companies, blue chip institutional investors, wealth managers, private equity and corporate finance houses to support their capital markets activity. Edison provides services to more than 420 retained corporate and investor clients from offices in London, New York, Frankfurt, Sydney and Wellington. Edison is authorised and regulated by the Financial Conduct Authority.

Edison is not an adviser or broker-dealer and does not provide investment advice. Edison's reports are not solicitations to buy or sell any securities.

For more information please contact: Maxim Jacobs, Edison Investment Research, +1-646-653-7027 Nathaniel Calloway, Edison Investment Research, +1-646-653-7036, healthcare@edisongroup.com Contact details: Learn more at http://www.edisongroup.com and connect with Edison on:  

LinkedIn  http://www.linkedin.com/company/edison-investment-research   Twitter    http://www.twitter.com/Edison_Inv_Res    YouTube    http://www.youtube.com/edisonitv   Google+    https://plus.google.com/105425025202328783163/posts 

SOURCE Edison Investment Research

Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
FDA expands use of PeriCoach at-home pelvic floor ...
S
TheraVasc Achieves Major Milestone in Development ...